NAD+

What the Human Trials Actually Found

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Randomised human data exists and is better than for most compounds in this catalogue, including trials published in Cell Metabolism, Science and GeroScience. Every one of them used a precursor rather than NAD+ itself, and the endpoints are largely biomarkers rather than clinical outcomes.

Key facts

NADPARK
Randomised phase I, NR, Parkinson's, Cell Metab 2022
Orr 2024
Randomised placebo-controlled, NR, older adults
Yoshino 2021
NMN, muscle insulin sensitivity, Science
Yi 2023
NMN efficacy and safety, GeroScience
Compound used
Precursors in all of them
Dominant endpoints
Biomarkers, not outcomes

NADPARK

Brakedal and colleagues published a randomised phase I trial of nicotinamide riboside supplementation in Parkinson's disease in Cell Metabolism in 2022. Phase I means the primary questions were safety and whether the intervention did what it was supposed to biologically, not whether it helped. Choosing Parkinson's reflects a specific mitochondrial hypothesis rather than a general ageing one.

Orr 2024

A randomised placebo-controlled trial of nicotinamide riboside in older adults, published in GeroScience in 2024. Placebo-controlled and randomised is the right design, and the population is the one the ageing hypothesis actually concerns. It is a real contribution, and it is modest in scale.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

Yoshino 2021

Published in Science in 2021, reporting that nicotinamide mononucleotide increased muscle insulin sensitivity in prediabetic women. Publication in Science reflects a notable result, and the endpoint (insulin sensitivity) is more physiological than a simple NAD+ level. It is one trial in one specific population.

The pattern across all of them

Precursors, not NAD+. Biomarker and mechanism endpoints more than clinical outcomes. Modest sample sizes. Early phases. This is a field with real randomised evidence at an early stage, which is substantially better than most of this catalogue and substantially short of what the surrounding commentary implies.

What is conspicuously absent

Large trials with hard clinical endpoints. Nothing here resembles the scale of the incretin programmes. TRIUMPH enrolled over 5,800 participants across multiple Phase 3 studies. NAD+ precursor research has produced good early evidence, not confirmatory evidence, and the difference is not a technicality.

And none of it concerns NAD+ as supplied here

The trials administered defined precursor preparations under clinical supervision with ethics approval. Material supplied for laboratory research is not those preparations and is not covered by those findings.

Frequently asked questions

Is there real human data on NAD+?

Yes. Randomised trials in Cell Metabolism, Science and GeroScience. All used precursors rather than NAD+ itself.

What did they measure?

Largely biomarkers and mechanism endpoints. Yoshino 2021 measured muscle insulin sensitivity, which is more physiological.

Is this strong evidence?

Real early-stage evidence, better than most of this catalogue. Not confirmatory. The trials are small and early-phase.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.